NR4A1 and breast cancer: It is remarkable that the distribution of the IICCs that we observed is similar to that seen in luminal hormone receptor-positive (HR+) breast cancer and invasive lobular HR+ breast cancer, with most of the cases investigated in this study having between 0 and 10% IICC, reflecting low recognition by immunity.